Search results
Results from the WOW.Com Content Network
Muscle atrophy is the loss of skeletal muscle mass. It can be caused by immobility, aging, malnutrition, medications, or a wide range of injuries or diseases that impact the musculoskeletal or nervous system. Muscle atrophy leads to muscle weakness and causes disability.
Cases of severe muscle atrophy or destruction may render the muscle too weak to show any reflex and should not be confused with a neuronal cause. [citation needed] Hyporeflexia may have other causes, including hypothyroidism, electrolyte imbalance (e.g., excess magnesium), and drug use (e.g, depressants). [1]
Babinski's sign; emotional lability; The importance of correctly recognizing progressive muscular atrophy as opposed to ALS is important for several reasons. The prognosis is a little better. A recent study found the 5-year survival rate in PMA to be 33% (vs 20% in ALS) and the 10-year survival rate to be 12% (vs 6% in ALS). [1]
Proximal diabetic neuropathy, also known as diabetic amyotrophy, is a complication of diabetes mellitus that affects the nerves that supply the thighs, hips, buttocks and/or lower legs. Proximal diabetic neuropathy is a type of diabetic neuropathy characterized by muscle wasting, weakness, pain, or changes in sensation/numbness of the leg.
According to Lopate, et al., methylprednisolone is a viable treatment for chronic inflammatory demyelinative polyneuropathy (which can also be treated with intravenous immunoglobulin). The authors also indicate that prednisone has greater adverse effects in such treatment, as opposed to intermittent (high-doses) of the aforementioned medication.
There is no standard course of treatment to slow or stop the progression of the disease as of 2019. [1] sIBM patients do not reliably respond to anti-inflammatory, immunosuppressant, or immunomodulatory medications. [31] Most of disease management is supportive care. [1] Prevention of falls is an important consideration. [1]
The hallmark sign of sarcopenia is loss of lean muscle mass, or muscle atrophy. The change in body composition may be difficult to detect due to obesity , changes in fat mass, or edema . Changes in weight, limb, or waist circumference are not reliable indicators of muscle mass changes.
Spinal type: Muscle weakness and atrophy as in other types of CMT, but set apart by being autosomal recessive inheritance. HMSN5: Charcot–Marie–Tooth with pyramidal features — 600361: Pyramidal type: onset between ages 5–12. Lower legs are affected first by muscle weakness and atrophy followed by the upper extremities.